Literature DB >> 18454140

p53-Driven apoptosis limits centrosome amplification and genomic instability downstream of NPM1 phosphorylation.

Maria Emanuela Cuomo1, Axel Knebel, Nick Morrice, Hugh Paterson, Philip Cohen, Sibylle Mittnacht.   

Abstract

Chromosome loss or gain is associated with a large number of solid cancers, providing genomic plasticity and thus adaptability to cancer cells. Numerical centrosome abnormalities arising from centrosome over-duplication or failed cytokinesis are a recognized cause of aneuploidy. In higher eukaryotic cells, the centrosome duplicates only once per cell cycle to ensure the formation of a bipolar mitotic spindle that orchestrates the balanced distribution of the sister chromatids to the respective daughter cells. Here we delineate the events that allow abnormal centrosome duplication, resulting in mitotic errors and incorrect chromosome segregation in cells with sustained cyclin-dependent kinase (CDK) activity. We have identified NPM1 as a substrate for CDK6 activated by the Kaposi's sarcoma herpesvirus (KSHV) D-type cyclin and shown that p53-driven apoptosis occurs downstream of NPM1 phosphorylation as a checkpoint mechanism that prevents accumulation of cells with supernumerary centrosomes. Our findings provide evidence that abnormal chromosome segregation in KSHV-infected cells is a direct consequence of NPM1 phosphorylation and predict that genomic instability is an inevitable consequence of latent KSHV infection.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18454140     DOI: 10.1038/ncb1735

Source DB:  PubMed          Journal:  Nat Cell Biol        ISSN: 1465-7392            Impact factor:   28.824


  23 in total

1.  Low molecular weight cyclin E overexpression shortens mitosis, leading to chromosome missegregation and centrosome amplification.

Authors:  Rozita Bagheri-Yarmand; Anna Biernacka; Kelly K Hunt; Khandan Keyomarsi
Journal:  Cancer Res       Date:  2010-06-08       Impact factor: 12.701

Review 2.  Kaposi's sarcoma and its associated herpesvirus.

Authors:  Enrique A Mesri; Ethel Cesarman; Chris Boshoff
Journal:  Nat Rev Cancer       Date:  2010-10       Impact factor: 60.716

Review 3.  Gammaherpesvirus and lymphoproliferative disorders in immunocompromised patients.

Authors:  Ethel Cesarman
Journal:  Cancer Lett       Date:  2011-04-13       Impact factor: 8.679

Review 4.  Chemosensitization of tumors by resveratrol.

Authors:  Subash C Gupta; Ramaswamy Kannappan; Simone Reuter; Ji Hye Kim; Bharat B Aggarwal
Journal:  Ann N Y Acad Sci       Date:  2011-01       Impact factor: 5.691

5.  Excess centrosomes induce p53-dependent senescence without DNA damage in endothelial cells.

Authors:  Zhixian Yu; Dana L Ruter; Erich J Kushner; Victoria L Bautch
Journal:  FASEB J       Date:  2017-06-16       Impact factor: 5.191

6.  Cyclin-cyclin-dependent kinase regulatory response is linked to substrate recognition.

Authors:  Maria Emanuela Cuomo; Georgina M Platt; Laurence H Pearl; Sibylle Mittnacht
Journal:  J Biol Chem       Date:  2011-01-13       Impact factor: 5.157

7.  At a crossroads: human DNA tumor viruses and the host DNA damage response.

Authors:  Pavel A Nikitin; Micah A Luftig
Journal:  Future Virol       Date:  2011-07       Impact factor: 1.831

8.  Chronic centrosome amplification without tumorigenesis.

Authors:  Benjamin Vitre; Andrew J Holland; Anita Kulukian; Ofer Shoshani; Maretoshi Hirai; Yin Wang; Marcus Maldonado; Thomas Cho; Jihane Boubaker; Deborah A Swing; Lino Tessarollo; Sylvia M Evans; Elaine Fuchs; Don W Cleveland
Journal:  Proc Natl Acad Sci U S A       Date:  2015-11-02       Impact factor: 11.205

9.  Nucleophosmin phosphorylation by v-cyclin-CDK6 controls KSHV latency.

Authors:  Grzegorz Sarek; Annika Järviluoma; Henna M Moore; Sari Tojkander; Salla Vartia; Peter Biberfeld; Marikki Laiho; Päivi M Ojala
Journal:  PLoS Pathog       Date:  2010-03-19       Impact factor: 6.823

Review 10.  Fanconi anaemia and cancer: an intricate relationship.

Authors:  Grzegorz Nalepa; D Wade Clapp
Journal:  Nat Rev Cancer       Date:  2018-01-29       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.